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supports this assertion by showing that 
polycystin-1 defi ciency was associated 
with increased sensitivity to IGF-1 as 
well as a permissive eff ect of cAMP on 
cell growth. Th e increase in cell prolif-
eration in response to both agents was 
found to be dependent on phosphati-
dylinositol-3′-kinase and ERK activity. 
It was reported previously that epider-
mal growth factor and cAMP regulate 
cell proliferation in ADPKD cystic cells, 
but, in contrast to IGF-1 in the report by 
Parker et al.,2 the mitogenic response to 
epidermal growth factor was the same 
between normal and cystic cells.10 Th is 
may represent an additional advantage 
from the therapeutic point of view, pro-
vided that this new pathway ends up 
being the most important in the deter-
mination of cyst-cell proliferation.
Inhibition of either Ras or Raf abol-
ished cell proliferation stimulated by 
IGF-1. Ras activation assays revealed 
signifi cantly higher IGF-1-stimulated 
levels of GTP-Ras in cyst cells compared 
with control cells, but cAMP alone had 
no eff ect on GTP-Ras levels. Th e mecha-
nism by which Ras and Raf are activated 
remains unclear.
Although there are still many steps 
of the complicated signaling pathways 
downstream from the PC1–PC2 com-
plex that remain obscure, the results of 
Parker et al.2 strongly suggest that inhi-
bition of Ras or Raf activation could be 
a useful therapeutic approach to reduce 
tubule-cell proliferation in ADPKD, 
ideally inhibiting cyst formation, and 
perhaps prolonging survival of func-
tional tubules. Th e future looks prom-
ising, exciting, based on the hope that 
translation of these fi ndings to animal 
models and eventually to clinical trials 
will bring much-needed treatment to 
ADPKD patients.
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Emerging role for fetuin-A as 
contributor to morbidity and 
mortality in chronic kidney 
disease
R Mehrotra1,2
Vascular calcification (VC) is an important reason for the high burden 
of vascular disease among chronic dialysis patients. Chronic kidney 
disease (CKD) is associated with increased promoters and decreased 
inhibitors of VC. The circulating levels of fetuin-A, a well-described 
inhibitor of calcification, regulate the cell-dependent process of 
osteogenesis. It is not surprising that the low circulating fetuin-A 
levels are associated with a greater prevalence and/or severity of 
VC and increased risk for all-cause and cardiovascular mortality. 
However, high circulating fetuin-A levels appear to induce insulin 
resistance and, in non-dialyzed subjects with diabetic nephropathy, 
are directly related to VC burden. These findings underscore the need 
to further clarify the multiple, systemic effects of fetuin-A and its role 
in health and various stages of CKD.
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Maintenance dialysis patients experi-
ence considerable morbidity and have 
a high mortality rate, particularly from 
vascular diseases. Accelerated vascular 
calcifi cation (VC) is but one of the sev-
eral important pathobiologic mecha-
nisms that contribute to the high burden 
of vascular disease in dialysis patients. 
In the setting of chronic kidney disease 
(CKD), VC is more severe and prevalent 
in both the intima and the media of the 
blood vessels — the former invariably 
occurs in the setting of atherosclero-
sis.1 It should be noted that none of the 
currently available noninvasive tools 
for the assessment of VC can reliably 
distinguish intimal from medial calci-
fi cation. Th us, in most human studies, 
the ascertained VC is a composite of 
intimal and medial calcifi cation.1 It had 
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long been believed that the high preva-
lence and severity of VC in CKD were 
a result of passive precipitation of cal-
cium phosphate, and this led to manage-
ment algorithms that cautioned against 
exceeding predesignated calcium × 
phosphorus products. Research over 
the last 15 years has shown that VC is 
an active and regulated, cell-mediated 
process wherein vascular smooth mus-
cle cells undergo a phenotypic change 
to osteoblasts or chondrocytes. Th ese 
cells, in turn, deposit hydroxyapatite, 
possibly by the release of mineral-laden 
matrix vessels and apoptotic bodies.1 
Studies also indicate that the degree of 
VC probably refl ects a balance between 
the promoters and the inhibitors of 
calcifi cation. CKD appears to be asso-
ciated with both an increased availabil-
ity of promoters (hyperphosphatemia, 
hypercalcemia, increased oxidized low-
density lipoprotein cholesterol, hyper-
leptinemia) and a decreased amount of 
inhibitors (matrix Gla protein, fetuin-
A). Th is may explain the markedly high 
prevalence and severity of VC in main-
tenance dialysis patients.
Hermans et al.2 (this issue) now further 
expand our knowledge of the possible 
role of a long-known calcifi cation inhibi-
tor, fetuin-A. Fetuin-A, a 62-kilodalton 
glycoprotein, is a member of the cysta-
tin superfamily of proteins. In humans, 
the 349-amino acid protein, as secreted 
from the liver, consists of two chains: a 
heavy and a light chain joined by a con-
necting segment and linked by disulfi de 
bonds.3 The N-terminal of the heavy 
chain consists of two cystatin domains, 
D1 and D2; the acidic amino acids in the 
D1 domain appear to account for fetu-
in’s ability to inhibit precipitation of cal-
cium and phosphorus.3 Indeed, fetuin-A 
accounts for up to one-half of the in vitro 
capacity of the serum to prevent the pre-
cipitation of calcium and phosphorus. 
It is now recognized that fetuin-A can 
actively regulate the cell-mediated proc-
ess of osteogenesis in the vessel wall. In 
the presence of calcium, fetuin-A binds 
to cell surface proteins, annexins II and 
VI.4 This binding facilitates the flow-
mediated entry of fetuin-A into the 
endosomes within the vascular smooth 
Table 1 | Key findings from the studies that have evaluated the association of serum fetuin-A and mortality in patients 
undergoing maintenance dialysis
Author, year 
[ref.] n Race HD/PD
Follow-up, 
months 
Relationship of serum fetuin-A to all-cause/
CV mortality
Relationship of serum 
fetuin-A to non-CV mortality
Ketteler et al.,
2003 [9]
312 White Prevalent HD 33 Significant association with all-cause/CV 
mortality non-significant on entering serum 
CRP in multivariate models
Not studied






42 (mean) Fetuin-A  levels below median for group 
significantly associated with all-cause 
(adjusted hazards, 2.58) and CV mortality 





238 Chinese Prevalent PD 32 (mean) Significant association with all-cause and CV 
mortality non-significant on entering serum 
CRP and valvular calcification in multivariate 
models
Not studied






34 (median) An increase of serum fetuin-A of 0.1 g per 
liter significantly associated with lower all-
cause mortality (adjusted hazards, 0.91), 
independent of serum CRP. Trend toward 
increased CV mortality
An increase of serum 
fetuin-A of 0.1 g per liter 
associated with lower non-
CV mortality (adjusted 
hazards, 0.89), independent 
of serum CRP
HD, hemodialysis; PD, peritoneal dialysis; CV, cardiovascular; CRP, C-reactive protein.
Figure 1 | A summary of proposed hypotheses to explain the low serum fetuin-A levels and the 
mechanisms that may underlie the associations of low fetuin-A with cardiovascular and non-
cardiovascular mortality in dialysis patients. 
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muscle cells.5 Intracellular fetuin-A 
inhibits apoptosis of vascular smooth 
muscle cells.6 It is also incorporated into 
the secreted matrix vesicles and apop-
totic bodies and therein inhibits miner-
alization in a concentration-dependent 
manner. Furthermore, it enhances the 
phagocytosis of apoptotic bodies by 
viable vascular smooth muscle cells, 
limiting their ability to nucleate calcium 
phosphate.6 Finally, fetuin-A antagonizes 
the action of bone morphogenetic pro-
tein-2, an important osteogenic protein 
that stimulates the first step in VC — 
the transdiff erentiation of calcifying vas-
cular cells.3
Several studies have demonstrated 
that maintenance dialysis patients have 
relatively low circulating fetuin-A lev-
els. Fetuin-A is a negative acute-phase 
reactant, and various cytokines, par-
ticularly interleukin-1β, decrease the 
synthesis of this glycoprotein. It is, 
thus, likely that the infl ammatory state 
associated with uremia is an important 
reason for low fetuin-A levels in dialy-
sis patients (Figure 1). Th e magnitude 
of the decrease in serum fetuin-A in 
the presence of infl ammation may be 
modulated by genetic predisposition 
(Figure 1).7 Furthermore, it is possible, 
though not consistently demonstrated, 
that genetic polymorphisms may deter-
mine fetuin-A levels independently of 
infl ammation. Finally, it is conceivable 
that the pro-calcifi cation milieu associ-
ated with uremia consumes circulating 
fetuin-A; this hypothesis, however, 
remains speculative.
As is discussed above, fetuin-A has 
the capacity to actively regulate the cell-
mediated process of VC. Th e importance 
of fetuin-A deficiency in the acceler-
ated VC observed in dialysis patients is 
underscored by the inverse relationship 
between serum fetuin-A levels and the 
presence of valvular calcifi cation or the 
severity of coronary artery calcifi cation.8 
Fetuin-A levels are also particularly low 
among patients with calcifi c uremic arte-
riolopathy. Moreover, three previous 
studies have demonstrated an inverse 
association between serum fetuin-A lev-
els and survival of dialysis patients (Table 
1), presumably as a result of accelerated 
VC (Figure 1).7–9 Th is association of low 
fetuin-A levels and all-cause mortality 
is confi rmed in the study by Hermans 
and colleagues.2 In 987 incident dialy-
sis patients (664 hemodialysis and 323 
peritoneal dialysis), an increase of serum 
fetuin-A by 0.1 g per liter was associated 
with a 9% lower adjusted risk for death 
during a median follow-up of 2.8 years.2 
In this study, the association of fetuin-A 
with all-cause mortality was independent 
of serum C-reactive protein levels — a 
fi nding consistent with the only other 
study of incident dialysis patients.2,7 
On the other hand, in the two reports 
of prevalent dialysis patients, fetuin-A 
levels lost their prognostic value when 
serum C-reactive protein levels were 
entered in multivariate models.8,9 Th ese 
apparently disparate fi ndings regarding 
the dependence of the association of 
fetuin-A and mortality on inflamma-
tion may have several possible expla-
nations. First, the study by Hermans 
et al.2 is substantially larger than those 
reported previously and thus has greater 
statistical power. Second, serum C-reac-
tive protein levels may be an imprecise 
measure of the link between fetuin-A 
levels and inflammation. Third, risk 
factors, including serum fetuin-A and 
infl ammatory markers, were ascertained 
only on one occasion in all these studies. 
Th us, none of the studies could capture 
the dynamic state of cardiovascular risk 
of the study subjects. Fourth, there may 
be heretofore unknown, infl ammation-
independent mechanisms that may lead 
to low serum fetuin-A levels in dialysis 
patients. Notwithstanding these apparent 
inconsistencies, the preponderance of in 
vitro, animal, and human studies support 
the notion that low serum fetuin-A lev-
els in dialysis patients are associated with 
increased risk for death, possibly second-
ary to accelerated VC (Figure 1).
However, the relationship of fetuin-A 
to vascular disease is far more complex 
than is suggested by the above discus-
sion. In patients with early CKD, fetuin-
A levels are not low and, among subjects 
with diabetic nephropathy, may be 
higher than in diabetics without CKD.10 
Fetuin-A inhibits the insulin-stimu-
lated autophosphorylation of the insulin 
receptor. Consistent with these fi ndings, 
serum fetuin-A levels are directly asso-
ciated with insulin resistance and with 
dyslipidemia, particularly hypertriglyc-
eridemia.10,11 Finally, in non-dialysis-
dependent CKD patients with diabetic 
nephropathy, serum fetuin-A levels are 
directly, not inversely, related to calci-
fi cation burden.10 Th ese fi ndings may 
make the job of defi ning ‘optimal’ serum 
fetuin-A levels particularly challenging. 
It should be noted that most of these 
studies are cross-sectional, and longitu-
dinal evaluation of fetuin-A levels may 
shed greater light on this issue.
A novel fi nding in the study reported 
by Hermans et al.2 is the association of 
low serum fetuin-A levels with non-
cardiovascular mortality. Non-cardio-
vascular causes of death represent a het-
erogeneous mixture of biologic processes 
— infectious causes constitute the single 
largest subgroup. Th e study had too few 
events in each subgroup of patients to 
meaningfully dissect the association of 
low serum fetuin-A with non-cardiovas-
cular causes of death. Moreover, the bio-
logic processes underlying this association 
are also not very well understood. Animal 
studies suggest that fetuin-A may promote 
phagocytic activity of macrophages, and 
thus, low fetuin-A levels may increase 
the risk of infection.12 Additional studies 
should be designed to further understand 
the nonvascular eff ects of fetuin-A.
To conclude, the available evidence 
seems to suggest that the low fetuin-A 
levels oft en observed in dialysis patients 
increase the risk for both cardiovascular 
and non-cardiovascular mortality. Th ere 
are currently no well-determined meth-
ods to change the levels of circulating 
fetuin-A. Nevertheless, upregulating 
fetuin-A levels may be a desirable goal; 
however, it should await our under-
standing of the deleterious vascular 
eff ects of high serum fetuin-A, particu-
larly arising from its role in inducing 
insulin resistance and dyslipidemia.
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The ins and outs of phosphate 
homeostasis
I Nemere1,2
A complication of chronic renal failure is hyperphosphatemia. An 
apparently straightforward manipulation to treat this — restriction 
of dietary phosphate — has proven that phosphate homeostasis is 
more complicated than we currently understand. This Commentary 
describes recent findings on novel regulatory factors that contribute 
to phosphate homeostasis.
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Th e study of phosphate homeostasis has 
received far less attention than calcium 
homeostasis for many decades. In part 
this is because phosphate is abundantly 
available in the diet whereas calcium is 
limited. However, there is increasing 
evidence that regulation of serum levels 
of phosphate through absorption in the 
intestine and excretion and reabsorption 
in the kidney is critical — for example, 
during growth, in hyperphosphatemia 
associated with chronic renal failure, 
and in X-linked hypophosphatemia.
In classical endocrine regulation, 
low serum phosphate induces the 
renal production of the seco-steroid 
hormone 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3). Low serum calcium 
signals the parathyroid glands to release 
parathyroid hormone (PTH), which 
likewise signals the kidney to increase 
production of 1,25(OH)2D3. Th is active 
metabolite of vitamin D acts to restore 
circulating mineral levels by increasing 
absorption in the intestine, reabsorption 
in the kidney, and mobilization of cal-
cium and phosphate from bone. Th us, 
chronic renal failure is associated with 
hyperparathyroidism, which in turn 
contributes to osteomalacia.
Another complication of chronic 
renal failure is hyperphosphatemia. 
Because the kidney is compromised in 
its ability to excrete phosphate, research 
has been devoted to assessing intestinal 
phosphate transport in nephrectomized 
rat model systems. Marks et al.1 (this 
issue) have, for the fi rst time, studied the 
eff ect of diet on such a model system in 
vivo. Uptake experiments using in situ 
intestinal loops showed that duodenal 
transport was greater than that in the 
jejunum but was unaff ected by nephrec-
tomy. Th e lower level of transport in the 
jejunum may be due to greater retention 
as measured in vitro. A low-phosphate 
diet tended to decrease transport in vivo 
but did not achieve a statistically signifi -
cant diff erence. Expression of Na/Pi-IIb 
cotransporter mRNA was also unaf-
fected by experimental manipulation 
in the intestine. In contrast, kidneys 
served as ‘positive’ controls in that this 
tissue showed diff erences in Na/Pi-IIa 
transporter mRNA levels with nephrec-
tomy and diet. Th e authors go on to note 
several therapeutic interventions that 
might be useful, such as the compound 
JTP-59557, a triazole derivative that 
inhibits Na/Pi-IIb.
Fibroblast growth factor 23 (FGF-23) 
has recently been recognized as a key 
mediator of phosphate homeostasis, its 
most notable eff ect being promotion of 
phosphate excretion. FGF-23 was discov-
ered to be involved in diseases such as 
autosomal dominant hypophosphatemic 
rickets, X-linked hypophosphatemia, and 
tumor-induced osteomalacia in which 
phosphate wasting was coupled to inap-
propriately low levels of 1,25(OH)2D3.
2 
In addition, mice in which the FGF-23 
gene has been deleted are hyperphos-
phatemic and have elevated serum 
